Consolidating gains and accelerating efforts to control and eliminate malaria in developing countries, particularly in Africa, by 2030 A/RES/72/309 at the international level for countries to ensure that drug efficacy and insecticide resistance testing is fully operational in order to enhance the use of artemisinin -based combination therapies and insecticides, and stresses that the data gathered should be utilized to inform local decisions and for further research and development of safe and effective therapies and new vector control tools; 29. Urges all Member States to prohibit the marketing and use of oral artemisinin-based monotherapies and to replace them with oral artemisinin-based combination therapies, as recommended by the World Health Organization, and to develop the financial, legislative and regulatory mechanisms necessary to introduce artemisinin combination therapies at affordable prices in both public and private facilities; 30. Recognizes the importance of the development of safe, affordable and cost-effective vaccines, new medicines and diagnostics to prevent and treat malaria and the need for further and accelerated research, including into safe, effective and high-quality therapies, using rigorous standards, including by providing support to the Special Programme for Research and Training in Tropical Diseases, 17 through effective global partnerships, such as, inter alia, the various malaria vaccine initiatives and the Medicines for Malaria Venture, where necessary stimulated by new incentives to secure their development, and through effective and timely support for the pre-qualification of new antimalarials and their combinations; 31. Also recognizes the importance of innovation in addressing the challenges to eliminating malaria, including the role of the World Intellectual Property Organization, in particular its Re: Search platform; 32. Calls upon the international community, including through existing partnerships, to increase investment in and efforts towards research to optimize current tools, develop and validate new, safe and affordable malaria -related medicines, products and technologies, such as vaccines, rapid diagnostic tests, insecticides and their delivery modes, to prevent and treat malaria, especially for at-risk children and pregnant women, and test opportunities for integration in order to enhance effectiveness and delay the onset of resistance; 33. Calls upon malaria-endemic countries to assure favourable conditions for research institutions, including the allocation of adequate resources and the development of national policies and legal frameworks, where appropriate, with a view to, inter alia, informing policy formulation and strategic interventions on malaria; 34. Reaffirms the right to use, to the fullest extent, the provisions contained in the World Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement), the Doha Declaration on the TRIPS Agreement and Public Health, the decision of the General Council of the World Trade Organization of 30 August 2003 on the implementation of paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health, and the latest amendment to article 31 of the TRIPS Agreement, which came into effect on 23 January 2017, and which provides flexibilities for the protection of public health, and in particular to promote access to medicines for all and to encourage the provision of assistance to developing countries in this regard, and calls for the broad and timely acceptance of the amendment to article 31 of the Agreement, as proposed by the General Council of the World Trade Organization in its decision of 6 December 2005, while recognizing that the protection of intellectual property is important for the development of new medicine; __________________ 17 18-15052 A joint programme of the United Nations Children’s Fund, the United Nations Development Programme, the World Bank and the World Health Organization. 9/12